After years of quiet focus on HIV and virology and stoic responses to flare-ups of attention over its pricing decisions, the new Gilead Sciences is ready to talk.
It’s got a revamped public affairs strategy that favors proactivity and aims to own the company’s narrative as it moves into oncology…
Click here to view original post
